Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors

Hepatocellular carcinoma (HCC) is a leading cause of mortality. Checkpoint inhibitors of programmed cell death protein‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have shown great efficacy, but lack biomarkers that predict response. Circulating tumor cells (CTCs) have promise as a liquid‐biopsy b...

Full description

Bibliographic Details
Published in:	Hepatology Communications
Main Authors:	Paul Winograd, Shuang Hou, Colin M. Court, Yi‐Te Lee, Pin‐Jung Chen, Yazhen Zhu, Saeed Sadeghi, Richard S. Finn, Pai‐Chi Teng, Jasmin J. Wang, Zhicheng Zhang, Hongtao Liu, Ronald W. Busuttil, James S Tomlinson, Hsian‐Rong Tseng, Vatche G. Agopian
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2020-10-01
Online Access:	https://doi.org/10.1002/hep4.1577

Similar Items

Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications
by: Jaeho Park, et al.
Published: (2025-02-01)

Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors
by: Zi Wan, et al.
Published: (2024-05-01)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
by: Jake S. O’Donnell, et al.
Published: (2016-10-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
by: Weiwei Xiao, et al.
Published: (2023-03-01)

Activation of PD-1/PD-L1 immune checkpoint by Zika virus.
by: Chenxi Wang, et al.
Published: (2025-09-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Optimizing PD-L1/PD-1 therapies: Immune checkpoint inhibitors in nasopharyngeal carcinoma
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
by: Domenico Ribatti, et al.
Published: (2024-07-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
by: Kazuhiko Hashimoto, et al.
Published: (2023-04-01)

Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation.
by: Ran Hu, et al.
Published: (2025-01-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
by: Megan Schollenberger, et al.
Published: (2017-08-01)

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01)

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
by: Ryunosuke Hoshi, et al.
Published: (2024-09-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
by: Takayuki Murata
Published: (2021-04-01)

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
by: Sadique A. Javed, et al.
Published: (2024-04-01)

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
by: Simona Serratì, et al.
Published: (2023-08-01)

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
by: Jose Lutzky, et al.
Published: (2017-11-01)

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model
by: Xue Zhang, et al.
Published: (2020-01-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
by: Iris Koopmans, et al.
Published: (2018-08-01)

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
by: Lisa Derosa, et al.
Published: (2018-06-01)

Coupling Lipid Labeling and Click Chemistry Enables Isolation of Extracellular Vesicles for Noninvasive Detection of Oncogenic Gene Alterations
by: Na Sun, et al.
Published: (2022-05-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma
by: Zeping Wang, et al.
Published: (2024-10-01)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
by: Pratibha Pandey, et al.
Published: (2022-03-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

The Immune Checkpoint Protein PD-L1 Regulates Ciliogenesis and Hedgehog Signaling
by: Ewud Agborbesong, et al.
Published: (2024-06-01)

Treatment of Hepatic Artery Thrombosis After Orthotopic Liver Transplantation
by: Ian Carmody, et al.
Published: (2004-07-01)

Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy  in Elderly Patients with Advanced NSCLC
by: Yunye MAO, et al.
Published: (2024-05-01)

Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
by: Zhikun Guo, et al.
Published: (2024-03-01)

CTLA-4 and PD-1/ PD-L1 immune checkpoint inhibitors in extensive stage small cell lung cancer
by: ZHENG Yang, et al.
Published: (2023-06-01)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
by: Alessandro Russo, et al.
Published: (2020-10-01)